<DOC>
	<DOCNO>NCT00854477</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics ( PK ) adjuvant capecitabine patient undergone proximal pancreatico-duodenectomy .</brief_summary>
	<brief_title>Pharmacokinetic Study Adjuvant Capecitabine After Resection Pancreatic Adenocarcinoma</brief_title>
	<detailed_description>Primary Objective : - To establish pharmacokinetics ( PK ) capecitabine patient undergone proximal pancreatico-duodenectomy . Secondary objective : - To establish toxicity profile capecitabine patient identify dose limit toxicity ( DLT ) . - To ensure equivalent capecitabine exposure compare previous study use patient undergone surgery . This clinical trial evaluate pharmacokinetics ( PK ) adjuvant capecitabine patient undergone proximal pancreatico-duodenectomy . The study also aim establish toxicity profile capecitabine patient , identify dose limit toxicity ( DLT ) , ensure equivalent capecitabine exposure compare previous study use patient undergone surgery . Screening test consist demographic detail , complete medical history , physical exam , vital sign , tumour serum marker , haematology biochemistry test . There also ECG , faecal elastase measurement serum urine pregnancy test ( woman childbearing potential ) . Haematology Biochemistry ( include CA19.9 ) repeat prior study drug administration . All patient receive 8 cycle oral capecitabine chemotherapy dose 1250 mg/m2 , administer twice daily 12 hourly interval 14 consecutive day 21 day cycle . Total proposed duration therapy 24 week , assume patient commence cycle without delay . Capecitabine metabolites ( DFCR , DFUR 5-FU ) plasma level measure 1st 3rd cycle patient . Treatment continue 8 cycle unless evidence disease progression , unacceptable toxicity .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Surgery include proximal pancreaticoduodenectomy Complete macroscopic resection ductal adenocarcinoma pancreas ( R0 R1 resection ) Histological confirmation primary diagnosis examination resection margin At least 4 week since surgery , fully recover operation fit take part trial Age ≥ 18 year World Health Organisation ( WHO ) performance status ≤ 2 ( Appendix 1 ) Haemoglobin ( Hb ) ≥ 9.0 g/dl Neutrophils ≥ 1.5 x 109/L Platelets ( Plts ) ≥ 100 x 109/L Serum bilirubin ≤ 1.5 x upper normal limit Alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) ≤ 2.0 x upper limit normal ( ULN ) Calculated creatinine clearance ≥ 50 ml/min ( uncorrected value ) isotope clearance measurement ≥ 50ml/min Female patient childbearing potential must negative serum pregnancy test prior enrolment agree use appropriate medically approve contraception four week prior enter trial , trial six month afterwards . Male patient must agree use appropriate medically approve contraception trial six month afterwards . Written , inform consent provide . Ability patient cooperate treatment follow must ensure document . Pregnancy Lactation Evidence malignant ascites , peritoneal liver metastasis , spread distant abdominal extraabdominal organ . Concurrent mechanical malabsorptive disorder preclude affective oral administration drug ( exclude malabsorption relate directly proximal pancreaticduodenectomy ) Patients pancreatic lymphoma histological diagnosis Macroscopically remain tumour ( R2 resection ) Patients high medical risk nonmalignant systemic disease include active uncontrolled infection . Patients condition Investigator 's opinion would make patient good candidate clinical trial . Patients know serologically positive Hepatitis B , Hepatitis C Human Immunodeficiency Virus ( HIV ) . History confirm Ischaemic Heart Disease , concurrent congestive heart failure prior history class III/ IV cardiac disease ( New York Heart Association [ NYHA ] refer Appendix 5 ) Any serious medical psychological condition preclude adjuvant treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>capecitabine</keyword>
	<keyword>Post whipples</keyword>
	<keyword>pancreatico-duodenectomy</keyword>
	<keyword>pancreatic adenocarcinoma</keyword>
	<keyword>pharmacokinetic</keyword>
</DOC>